For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Cellular Peptide
FOXO4-DRI
A D-retro-inverso peptide designed to interfere with the FOXO4–p53 interaction, used in senescence research to study selective clearance of senescent cells in culture and animal models.
Quantity
$148.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
FOXO4-DRI
1 × 10mg · $148.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
10mg
99.70%latest
| Tested | Measured | Purity |
|---|---|---|
| May 2026 | 13.11mg | 99.70% |
| Jan 2026 | 11.97mg | 99.78% |
| Dec 2025 | 12.37mg | 99.72% |
| Oct 2025 | 12.33mg | 99.73% |
Frequently researched together
Commonly studied alongside FOXO4-DRI.
Compound information
Technical specifications
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- Nature communications
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
2025·DOI: 10.1038/s41467-025-60844-9·PMID: 40593617Bourgeois B, Spreitzer E, Platero-Rochart D, Paar M, Zhou Q, Usluer S
View source - Frontiers in bioengineering and biotechnology
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
2021·DOI: 10.3389/fbioe.2021.677576·PMID: 33996787Huang Y, He Y, Makarcyzk MJ, Lin H
View source - Aging
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
2020·DOI: 10.18632/aging.102682·PMID: 31959736Zhang C, Xie Y, Chen H, Lv L, Yao J, Zhang M
View source - Naunyn-Schmiedeberg's archives of pharmacology
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline
2026·DOI: 10.1007/s00210-026-05309-6·PMID: 42024235Alameen AAM, Al-Kuraishy HM, Fawzy MN, Batiha GE
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.